Opendata, web and dolomites


New vaccine for a paradigm shift in Brucellosis

Total Cost €


EC-Contrib. €






 BGV1 project word cloud

Explore the words cloud of the BGV1 project. It provides you a very rough idea of what is the project "BGV1" about.

normally    ups    animal    travelling    prevalent    revenue    mass    projection    diagnostic    tam    tool    livestock    hospital    inconveniences    13m    income    eradication    compensation    86    treatments    pregnant    costly    standard    first    preventing    vaccination    countries    requiring    disease    programs    regions    global    forecast    vaccine    3bn    losses    accounting    vaccines    devastating    500    recommended    bioterrorism    patented    prohibited    76bn    humans    farmers    interfering    infected    shift    rational    residual    trading    92    conservative    economic    virulence    human    zoonotic    appropriate    accumulated    slaughter    generating    africa    check    lactating    reaching    time    profits    threat    15    techniques    58    mediterranean    02m    bgv1    consistently    place    anywhere    outbreaks    estimate    latam    international    radical    exists    asia    infect    ranked    people    annually    29m    paradigm    simplifies    causes    net    infection    animals    benefits    endemic    tests    brucellosis    restricted    world    prevalence    candidate   

Project "BGV1" data sheet

The following table provides information about the project.


Organization address
address: PLAZA LAMITURRI, 10, 1 A
postcode: 31192
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRUCELLA GREEN VAC SL ES (MUTILVA) coordinator 50˙000.00


 Project objective

Brucellosis is consistently ranked as the world’s most common and widespread zoonotic disease, meaning that it normally exists in animals but it can also infect humans. In livestock, it causes devastating production losses in low-income countries accounting in more than €3bn per year. In humans, there are 500,000 new cases annually requiring long-term hospital treatments. Brucellosis is endemic in most Asia, Africa and LATAM and is prevalent in the EU Mediterranean regions. Also, outbreaks may take place anywhere in a global world with international trading, people travelling all around the world and potential threat of bioterrorism.

Since human vaccines are not available, the most rational approach for preventing human brucellosis is the control and eradication of infection in animals. Animal vaccines are an essential tool, but existing vaccines own some inconveniences, such as residual virulence, complex management systems and costly diagnostic techniques that are not appropriate for developing countries; in Europe, control programs are based in tests for animal check-ups and compensation to farmers for slaughter of the infected animals, with vaccination prohibited or highly restricted to areas with higher prevalence of Brucellosis. These inconveniences recommended the development of new candidate vaccines.

We are developing BGV1, a patented vaccine that has the potential of allowing, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. It also simplifies existing vaccine management systems as it can be used without interfering standard diagnostic techniques. In our 5-year forecast, we estimate accumulated revenue and net profits of €58.29m and €15.13m, a conservative projection by just reaching 86.02m animals that represent only 3.92% of our TAM, generating 1.76bn economic benefits to our users.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BGV1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BGV1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TalentVision (2019)


Read More  


Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More  

Project Tracworx (2019)

Tracworx is a data analytics tool that allows you to establish bottlenecks in your patient flow, while understanding your efficiencies and ultimately your true capacity.

Read More